With a combined revenue of $21 trillion and $2.1 trillion in profits, the 2026 Fortune 500 is the definitive list of America's largest companies.

Fortune 500

AI is a major force shaping this year’s list—but it’s far from the only story.

World's Most Admired Companies

Almost $20 trillion in revenue—and a record-breaking $1.87 trillion in profits. Introducing the 2025 Fortune 500, the definitive list of the biggest companies in America.

The companies on this list are mobilizing the creative tools of capitalism to help solve social problems.

Health care product distributor Henry Schein has redoubled its effort to provide in-kind donations and grants to disaster-stricken areas, as well as to work with NGOs to proactively supply vulnerable areas with medical and dental supplies—so supplies are there even if roads or airports become unusable. Its Global Product Donation Program has donated over $75 million in health care supplies to health centers and clinics since its 1998 inception. Henry Schein also provides $10,000 in cash grants and $25,000 in products through its Prepare to Care Program to each of five nonprofit partners committed to disaster-relief preparedness and immediate assistance in natural disaster-prone areas.

Change the World

Industries included in the sector are insurance and managed care, medical products and facilities, pharmacy services, and pharmaceutical companies.

Fortune Sector Leaders: Health Care

The Fortune 500, in its 70th year in 2024, ranks the biggest U.S. companies by revenue.

The 25th Fortune World’s Most Admired Companies list suggests that tech giants’ peers respect them as much as ever.

The Fortune 500, in its 69th year in 2023, ranks the biggest U.S. companies by revenue.

Just as it dominates our economy, Big Tech now dominates Fortune’s annual ranking of corporate reputation.

Fortune's annual list dedicated to the idea that business is uniquely suited to address society’s biggest challenges.

CTW.1122.Henry Schein

As with many aspects of daily living, the standard dentist visit was not designed with much consideration for the needs of those with disabilities. For some, the experience may be physically inaccessible; for others, like those with developmental disabilities such as autism, the environment and experience—with its bright lights, buzzing noises, and close contact—can be terrifying and traumatic. Meanwhile, in part due to those challenges, people with disabilities suffer higher rates and more severe cases of periodontal disease, gum disease, and untreated cavities—all conditions that can lead to other health problems. Henry Schein, the dental and medical supply company, began work to address this disparity more than a decade ago, forging partnerships—like Project Accessible Oral Health—to increase training and adapt dental practices to better serve disabled people. The efforts have resulted in provision of specialized services to hundreds of thousands of children as well as a new dental school curriculum, developed with stakeholders like the American Dental Education Association.

This year’s Fortune 500 marks the 68th running of the list.

After a year in which humanity leaned more heavily than ever on tech giants, see which companies topped Fortune's ranking of corporate reputation.

This year’s Fortune 500 marks the 67th running of the list.

Founded by its namesake as a Queens, N.Y., pharmacy in 1932, the company is now one of the world's largest distributors of dental supplies and other medical goods, operating in more than 30 countries. An ever-present on Fortune's list of the <a href="https://fortune.com/worlds-most-admired-companies/">World's Most Admired Companies</a>, it is considered by many in its sector as a leader in social responsibility. With $10.1 billion in sales last year, Henry Schein moved up six spots on this year's Fortune 500 list.

For an astounding 13th straight year, Apple claims the top spot in Fortune’s annual ranking of corporate reputation, based on a survey of almost 3,800 executives, directors, and analysts.

This year's Fortune 500 marks the 66th running of the list.

F500-2020_304_Henry-Schein

Long Island's largest public company by revenue, Melville, N.Y.-based Henry Schein globally distributes medical and dental supplies including vaccines, pharmaceuticals, financial services, and equipment. The company kicked off 2019 by spinning out its animal health unit in an attempt to focus on its core medical and dental businesses; it ended the year with the novel coronavirus pandemic eroding its business.

As we face unprecedented collective challenges, cooperation has become a business superpower.

19.CTW20.21.Henry-Schein

Five years ago, well before COVID-19 entered the lexicon, Henry Schein CEO Stan Bergman called on his peers at the World Economic Forum to think collectively about pandemic preparedness. It worried him that there was no organized emergency product list, and no directory of where to get such products when emergency struck. Soon after, Bergman’s dental and medical supply company became a founder and the private-sector lead of the Pandemic Supply Chain Network, a public-private partnership whose members include the World Health Organization, the World Bank, UPS, and more than five dozen health care manufacturers. 
 
The group created a platform to convene responders and exchange information. Says Bergman: “You can’t do it in the middle of a pandemic. You’ve got to exchange business cards well before.” The network functioned well in recent Ebola outbreaks, and in response to COVID-19, it has sourced more than $200 million worth of critical supplies, like masks, gowns, and swabs, so far.

Here are the World's Most Admired Companies for 2019 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 65th running of the list.

Here are the World's Most Admired Companies for 2018 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 64th running of the list.

Here’s our look at 57 companies that do well by doing good.

Here are the World's Most Admired Companies for 2017 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 63rd running of the list.

Here are the World's Most Admired Companies for 2016 as ranked in their industries. See who made the list.

This year's Fortune 500 marks the 62nd running of the list.

Business insiders have spoken: Asked which companies they most admire, more than 4,100 executives, directors, and analysts chose these top 50 All-Stars.

This year's Fortune 500 marks the 61st running of the list. Wal-Mart claims the top spot again. See who made the list.

Wal-Mart stayed on top as its sales crept closer to half-a-trillion dollars. Apple moved into the top five. And UnitedHealth Group continued its steady climb. 

Change The World

Impact Segment

Sector

Prior Year Rank

Industry

Current All-Star Rank

Previous All-Star Rank

Industry Rank

Previous Industry Rank

Overall Score

Innovation

People Management

Use of Corporate Assets

Social Responsibility

Quality of Management

Financial Soundness

Long-Term Investment Value

Quality of Products/Services

Global Competitiveness

Key Financials (last Fiscal Year)

Revenues ($M)

Profits ($M)

Assets ($M)

Total Stockholder Equity ($M)

Profit Ratios

Profit as % of Revenues

Profits as % of Assets

Profits as % of Stockholder Equity

Earnings Per Share (last Fiscal Year)

Earnings Per Share ($)

EPS % Change (from prior fiscal year)

EPS % Change (5 year annual rate)

EPS % Change (10 year annual rate)

Total Return

Total Return to Investors (last year)

Total Return to Investors (5 year, annualized)

Total Return to Investors (10 year, annualized)

Henry Schein is a global health care services distributor of dental and medical supplies, business and supply-chain solutions, and tech-forward integrated care solutions. The nearly century-old company operates in over 30 countries and has developed more than 300,000 products, from diagnostics to surgical and orthopedics, including whitening strips, dental implants, patient communication services, and a dual-cuff blood pressure monitor. In early 2025 the company acquired Acentus, a national medical supplier of continuous glucose monitors, to expand its portfolio. Henry Schein has been named among the World’s Most Ethical Companies by Ethisphere for 13 consecutive years.

Q2 2026

Q1 2026

Q4 2025

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Q3 2024

Henry Schein (HSIC): Company Profile, Stock Price, News, Rankings

legacy

Henry Schein

henry schein

Good morning, ladies and gentlemen, and welcome to Henry Schein's Second Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. Later, we will conduct a question and answer session. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Graham Stanley, Henry Schein's Vice President of Investor Relations and Strategic Financial Project Officer. Please go ahead, Graham.

Thank you, operator, and my thanks to each of you for joining us to discuss Henry Schein's financial results for the 2025. With me on today's call are Stanley Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein and Ron South, Senior Vice President and Chief Financial Officer. Before we begin, I'd like to state that certain comments made during this call will include information that's forward looking. Risks and uncertainties involved in the company's business may affect the matters referred to in forward looking statements and the company's performance may materially differ from those expressed in or indicated by such statements. These forward looking statements are qualified in their entirety by the cautionary contained in Henry Schein's filings with the Securities and Exchange Commission and included in the Risk Factors section of those filings.

In addition, all comments about the markets we serve, including end market growth rates and market share, based upon the company's internal analyses and estimates. Today's remarks will include both GAAP and non GAAP financial results. We believe the non GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable the comparison of financial results between periods where certain items may vary independently of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding GAAP measures. Reconciliations between GAAP and non GAAP measures are included in Exhibit B of today's press release and can be found in the Financials and Filings section of our Investor Relations website under the Supplemental Information heading and in our quarterly earnings presentation also posted on our Investor Relations website.

The content of this conference call contains time sensitive information that is accurate only as of the date of the live broadcast 08/05/2025. Henry Schein undertakes no obligation to revise or update any forward looking statements to reflect events or circumstances after the date of this call. Lastly, during today's Q and A session, please limit yourself to a single question and a follow-up. And with that, I'd like to turn the call over to Stanley Bergmann.

Thank you, Graham. Good morning, everyone. Thank you for joining us. We had good sales growth in our Global Distribution Group this quarter, while experiencing lower margins in The U. S.

Versus the prior year, primarily resulting from lower glove pricing as well as some time limited targeted sales initiatives. We are pleased with the results from these initiatives and have returned to normal levels of promotional activity. Strong merchandise sales in July caused us to be optimistic about these results. Our Specialty Products and Technology groups continue to deliver strong results, driven primarily by sales from innovative products, solutions and cost efficiencies. And July sales also continued to be strong.

We are maintaining our full year guidance, which continues to reflect earnings weighted to the second half of the year. We expect 2025 to be the base year from which to grow and achieve our previously provided long term goal of high single digit to low double digit earnings growth. We are partnering with KKR's Capstone. We have engaged two leading global management consulting firms to support our efforts to enhance distribution gross margins, including accelerating sales of our owned products portfolio and support our ongoing company wide initiatives to increase efficiencies. We expect these projects, which expand on our Bold plus one strategy, to start producing results towards the 2026 and will support our ongoing initiatives to drive superior customer satisfaction and our financial goal of high single digit to low double digit earnings growth.

We expect these projects to streamline processes, partially through introducing new technology, including AI solutions, thereby enhancing the customer experience and improving efficiencies. Let me touch on a few of the highlights from the quarter that advanced our Bold plus One strategic plan. Overall, we believe we are continuing to gain market share across the portfolio. Our customers highly value our price value commercial model, which encompasses technical support, the industry's broadest product offering, including corporate brand, customer loyalty programs, advanced value added services, business analytics and reliable next day high fulfillment. We achieved over 45% of our non GAAP operating income from high growth, high margin businesses during the quarter, driven by sales growth and profitability in our high growth, high margin businesses, which outpaced growth in the rest of the business.

We remain on track to achieving our goal of 50% over 50%, shall we say, of our total non GAAP operating income coming from these businesses, plus in addition to that, 10% or more coming from our corporate brands. In The United States, our Medical business continued to show strong results, including our home solutions platform, underscoring the strength of our strategy of following the patient into the home. We continue to implement initiatives to right size expenses in our distribution businesses and corporate functions and consolidated various manufacturing facilities. We now expect the run rate for these savings to be slightly over $100,000,000 by the end of the year. And beginning in 2026, we expect further enhanced profitability as a result of our new value creation initiatives.

And after our team successfully launched our new global e commerce platform, Henry Schein dot com in The UK and Ireland, we have begun a phased launch in North America, first in Canada and now in The United States that will continue into the fourth quarter. Turning now to review of our businesses, let me start with the Global Distribution and Value Added Services Group. We achieved volume growth in our U. S. Dental merchandise business, but at lower average selling prices compared with the 2024, primarily due to glove pricing and limited targeted sales initiatives.

We have also invested in sales talent. And as mentioned earlier, along with our targeted sales initiatives, we expect this will accelerate merchandise growth as reflected in our July sales results. U. S. Dental equipment sales were temporarily impacted by market uncertainty related to tariffs in the second half of the quarter.

Dentists are continuing to invest in their practices and the order intake has since returned to normal. There was a rebound in new office design activity in June and our equipment backlog recovered with some of these installations being deferred into the third quarter. Overall, this supports our view that the equipment sales will improve in the second half of the year. We are seeing good volume growth in the digital equipment arena, but at a lower average selling price as growth has primarily come from entry level intraoral scanners. Moving on to The United States business The United States Medical business.

Sales grew mid single digit for the quarter. Patient traffic increased steadily. Our sales reflected strong growth in Medical Products and Pharmaceuticals, particularly sorry, partially driven by new accounts and the continued outperformance by our Home Solutions business. International Dental merchandise sales growth was steady during the quarter, although April was impacted by the timing of Easter. Sales growth was particularly strong in Brazil.

International Dental Equipment sales growth was strong in Canada and across Europe, particularly in traditional equipment. Growth was bolstered by this year's International Dental Show in Cologne. Digital Equipment volumes grew well with sales at a lower selling price lower average selling price. Sales of Parts and Service in both The U. S.

And internationally continued to grow well in the mid single digits. Value Added Services sales growth was impacted again this quarter by lower sales in our practice transitions business as a result of a high prior year comparable. This is a high margin business with sales fluctuate quite a bit from quarter to quarter. We have a strong pipeline of active transactions that we expect to close throughout the remainder of the year. So let's now go to the Global Specialty Products Group.

As a result, this group includes as a reminder, this group includes implants and biomaterials as well as endodontics, orthodontics and orthopedic products. Sales in the second quarter reflected accelerated accelerating growth in Dental Implants and Biomaterials and Interdontic Consumables. Profits were also bolstered by our recent consolidation of manufacturing facilities. We are pleased with the sales growth of our Implants business, which grew mid single digit in constant currency and we believe that we continue to gain market share in the Implant and Bone Regeneration area. Specifically, we achieved double digit growth in value implants driven by our SIN and BioTek Dental Implant systems that were complemented by low single digit growth in our premium brand, BioHorizons Camelot.

Our U. S. Implant sales grew low single digits and reflected the continued rollout of the BioHorizons tapered pro conical implant, which is gaining momentum. Smart shaped Healer abutments sales also continue to grow, supported by the expansion of our ThyHorizon sales force in The U. S.

This expansion is expected to increase sales on a continued accelerating sales growth basis. European implant growth this quarter was impacted by the timing of Easter. Momentum accelerated later part of the quarter and the business is doing well in the third quarter. Orthodontics remain a small part of the Specialty Products business and we continue to work to improve this business. Now finally, our Global Technology Group sales accelerated during the quarter, driven by strong growth in our core practice management system solution business, particularly our cloud based platforms, including Dentrix Ascend in North America and entirely outside of North America, as well as strong growth in our revenue cycle management offerings, including e claims, electronic billing and patient messaging.

As a result, we are driving growth in annual recurring SaaS subscription revenues and increasing adoption of transactional services. Practice Management software growth was in the mid double digits driven by a 20% year over year increase in cloud based customers. We now have over 10,000 customers subscribed to the Dentrix Ascend and Bentali systems. We believe our OneShine marketing approach enables greater customer adoption of the Henry Schein One platform and provides us with a unique competitive advantage. This platform differentiates us by seamlessly integrating workflows through technology to create meaningful operational efficiencies.

Our workflow integration deepens customer engagement and reinforces our ability to deliver scalable reoccurring solutions and revenue growth. The overall technology business and our own brands businesses, specialty businesses are all doing well. Let me comment for a minute on the announcement that I'll be retiring as CEO at the end of the year while continuing to serve as Chairman of the Board. It has been an incredible journey over the past forty five years and I'm very pleased with all that Team Schein has accomplished over this time. Many transitions from a mail order, a small mail order dental distribution business to a global provider of products and services to the dental community and to the ultimate care site.

Many, many changes along the way, expansion of the product and strength the product offering, the services we offer and strengthening of our management team as well as the team in general. It has been especially gratifying to have worked with the tens of thousands of incredibly committed and talented Team Schein members who re imagined and reinvented Henry Schein's role, as I mentioned, from one of product delivery and logistics, Juwana's mission today is to help over 1,000,000 healthcare professionals operate better and more efficient practices so that our customers can focus on outstanding clinical care. Thank you to each and every Team Schein member for your individual and collective efforts in playing such an important part in building our unique company. Thank you to our investors for your support in almost thirty years as a public company come full thirty years come this November. As part of succession planning over the years, the company is focused on developing the next generation of leaders and earlier this year simplified the business by separating into three operating divisions, each with outstanding leadership.

I fully expect that Andrea Albertini, CEO of the Global Distribution Group who also has responsibility for the Global Technology Group from our investment point of view and Tom Popak, CEO of the Global Specialty Group together with the rest of the company's Executive Management Committee. I expect these two leaders together with the EMC to elevate Henry Schein to new heights, continuing to advance the Bold plus One strategy in conjunction with KKR value creation initiatives and a broad based employee ownership program. Guided by our purpose driven mission, we've built an agile company that meets the evolving needs of our customers with much more to come. We've also created significant shareholder value and positioned Henry Schein for continued growth and success. Of course, I remain fully committed to Team Schein and look forward to working with the Board to identify my successor and effect a smooth transition.

I'm committed to doing this, of course. In the meantime, the team remains focused on advancing our Bold plus One strategy, thereby driving value for our customers and of course our shelves. Let me now turn the call over to Ron to review our second quarter financial results and discuss our 2025 financial guidance. Ron,

Thank you, Stanley, good morning, everyone. As usual today, I will review the financial highlights for the quarter and would like to remind investors that on our Investor Relations website, we have also included a financial presentation containing additional detailed financial information. Starting with our second quarter sales results, I will provide details on total sales growth as well as constant currency sales growth compared with the prior year. Global sales were $3,200,000,000 with sales growth of 3.3% compared with the 2024. Constant currency sales grew 2.7% with 0.6% attributable to foreign currency exchange and 0.8 growth from acquisitions.

Our GAAP operating margin for the 2025 was 4.67%, a decrease of 42 basis basis points compared with the prior year GAAP operating margin. On a non GAAP basis, the operating margin for the second quarter was 6.96%, a decrease of 79 basis points compared to the prior year non GAAP operating margin, driven by lower gross margins within our U. S. Distribution business due to lower glove pricing as well as targeted initiatives to accelerate growth in market share. In addition, operating income was impacted by higher operating expenses compared to the prior year, attributable to acquired companies, foreign exchange, increased technology and marketing investments in anticipation of the launch of henryschein.com and non income tax credits in the prior year that did not recur this year.

We continue to drive improved operational efficiency by integrating acquisitions and restructuring as well as executing our new value creation programs. Second quarter twenty twenty five GAAP net income was $86,000,000 or $0.70 per diluted share. This compares with prior year GAAP net income of $104,000,000 or $0.80 per diluted share. Second quarter twenty twenty five non GAAP net income was $135,000,000 or $1.1 per diluted share. This compares with prior year non GAAP net income of $158,000,000 or $1.23 per diluted share.

Adjusted EBITDA for the 2025 was $256,000,000 compared with second quarter twenty twenty four adjusted EBITDA of $268,000,000 Turning to our sales results. The components of sales growth for the second quarter are included in Exhibit A to this morning's earnings release. So I will provide the primary highlights of the main sales drivers for each reporting segment, starting with our Global Distribution and Value Added Services group. U. S.

Dental merchandise sales declined 1.2% resulting from increased volume offset by lower product pricing. U. S. Dental equipment sales declined 4.7% resulting from economic uncertainty beginning in May. Both traditional and digital equipment sales growth declined.

As Stan mentioned, there was a rebound in new office design activity in June and we expect equipment sales to grow in the second half of the year. We are pleased that sales grew by 6.3% in our U. S. Medical Distribution business, reflecting increased patient traffic and our Home Solutions business having another strong quarter. International Dental merchandise sales grew 1.9% or 0.5% in constant currency and was impacted by the timing of Easter.

International Dental equipment sales were good and grew 12.1% or 9.1% in constant currency, driven by strong sales growth in Canada, Germany and Austria and New Zealand. Finally, global value added services sales grew 3.6%. Sales growth was impacted this quarter by lower sales in our practice transitions business, partially a result of a tough comparison in the prior year. Turning to the Global Specialty Products Group, sales grew 4.2% or 3.3% in constant currency. Our implant and biomaterial business experienced solid growth in the second quarter, including double digit growth in our value implants and low single digit growth in premium implants.

Our orthodontic business sales declined year over year, but at a slower pace than in prior quarters. As we previously discussed, this business is being reorganized to support future profitable growth. We also had strong results in the Global Technology Group with total sales growth of 7.4% or 6.6% in constant currency. In The U. S, sales growth was driven by revenue cycle management and practice management software with double digit growth in Ascend.

Internationally, sales growth was primarily driven by our Dentale cloud based practice management solutions as well as strong growth in Canada. Turning to restructuring. Our restructuring expenses in the second quarter were $23,000,000 or $0.13 per diluted share. These expenses mainly relate to severance benefits. We now expect to achieve annual run rate savings of over $100,000,000 by the 2025, which is when the current plan is expected to have been completed.

As Stan mentioned, we have initiated two important value creation projects to enhance distribution gross margins, including accelerating sales of our own products portfolio as well as company wide initiatives to increase efficiencies. We will provide a further update on these initiatives on our upcoming third quarter earnings call. Regarding share repurchases, during the 2025, the company repurchased approximately 3,700,000.0 shares of common stock at an average price of $70.88 per share for a total of $259,000,000 This included approximately 3,100,000.0 shares of common stock under the previously announced accelerated stock repurchase plan at an average price of $71.6 per share for a total of $223,000,000 which followed the company's sale of 3,300,000.0 shares of common stock at an average price of $76.1 per share for a total of $250,000,000 to KKR. The ASR plan was completed in July. In addition to the ASR plan, the company repurchased approximately 500,000.0 shares of common stock at an average price of $67.36 per share for a total of $36,000,000 The impact of these share repurchases on second quarter diluted EPS was immaterial.

At the end of the quarter, we had $432,000,000 authorized and available for future stock repurchases, plus a further $27,000,000 authorized under the ASR, which as mentioned has not been completed. Turning to our cash flow, we generated operating cash flow of $120,000,000 in the 2025. We still expect operating cash flow to exceed net income for the full year. This quarter, we invested additional inventory in The U. S.

As part of our plan to mitigate the effects of tariff increases. Our accounts receivable also increased slightly in line with sales growth. As a reminder, working capital was still returning to normal levels in the second quarter of the prior year following the cyber incident resulting in stronger than normal cash flow. Let me conclude my remarks with a discussion of financial guidance. At this time, we are not able to provide without unreasonable effort an estimate of restructuring associated with the restructuring plan for 2025.

Therefore, we are not providing GAAP guidance. We are maintaining our 2025 financial guidance. As a reminder, this is as follows. We expect non GAAP diluted EPS attributable to Henry Schein Inc. To be in the range of $4.8 to $4.94 2025 adjusted EBITDA is expected to grow in the mid single digits versus 2024 adjusted EBITDA of $1,100,000,000 2025 total sales growth is expected to be 2% to 4% over 2024 and we expect a non GAAP effective tax rate of approximately 25%.

Our guidance assumes that foreign currency exchange rates will remain generally consistent with current levels, but the effects of tariffs can be mitigated and also includes expected remeasurement gains related to the purchase of controlling interest of previously held non controlling equity investments consistent with our business strategy. Our 2025 guidance is for current continuing operations and includes acquisitions that have closed. It does not include the impact of restructuring expenses and other items detailed in our press release. With that, I'll now turn the call back to Stanley.

Thank you, Ron. Thank you everyone again for calling in. So We believe Henry Schein is well positioned to accelerate growth. Of course, we're happy to answer any questions that investors may have. With respect to our distribution business, we are pleased with the results from the time limited targeted sales initiatives, which together with the rebound in equipment orders and momentum in our Medical business sets us up well for growth for the second quarter for the second half, third and fourth quarter.

The results from our technology, value added services and specialty businesses are strong and we look forward to this continuing into the second half of the year as well. We are also excited about the significant opportunities from our new value creation initiatives and we are optimistic about returning to high single digit, low double digit earnings growth. So with that overview, operator, we're ready to take questions from investors.

Thank you. We will now be conducting a question and answer session. Our first question comes from Jason Bednar with Piper Sandler. Please proceed with your question.

Good morning, everyone. Stan, a big congrats on your announced retirement. You've had such an enormous impact over the years in the dental community, the investor community, your employees. You're going to be missed around here. For my first question, I did want to start with the dental business and hoping to touch on a couple of topics.

One, you referenced a good July for merch without those above normal promotions continuing. Maybe you can give a bit more color on what you're seeing with respect to patient traffic, spending the dental office and just the confidence you have on the sustainability of these better trends that you were seeing in July? And then two, can you talk about the customer conversation around price increases from tariffs and how you're navigating these discussions to both retain share and protect margins?

Thank you, Jason, for your compliments on my years here at Henry Schein and my retirement. I have to say it's been a pleasure working with the analysts that cover us. I mentioned to our team earlier on as we've prepared for this call. This is my one hundred and nineteenth call with investors. And although every quarter is a challenge, never easy in a public company, I've really enjoyed working with The Street very much, I've learned a lot.

July trends, July trends at Henry Schein are positive. We're quite pleased with the momentum. In fact, I spent a little time last night with our senior dental sales team who were in town for a strategic meeting and they feel very strong. There were customers we had that had left us during the cyber incident and these promotions got them back, many of them back. And I think our customers understand the value that we provide as they test us, the ones that left and as they test more and more our systems, not only for consumables, but for equipment and the value added services.

So across the board, we're having a good July from a sales point of view and from a general understanding by our customers of the services that we offer. As it relates to patient traffic, we generally believe that in the markets that we serve, now there are parts of dentistry that we don't serve in a significant way, but the parts that we service, we believe that patient traffic is relatively stable. Of course, there are some challenges in specific countries, but there are also other countries where maybe it's a little positive, but we are doing very well. Overall, we believe that patient traffic in our Dental Distribution businesses continues to be flat globally. So that's traffic per se, but we as we noted, we continue to believe that we are either maintaining or actually growing market share across the board.

We believe in The U. S. For the Dental merchandise sales, which is flat with some price increases relating to tariffs, but generally not much price increase from manufacturers and because of the tariffs, because customers are concerned with pricing, customers are moving towards our own brands and I have to say also to brands and manufacturers that are prepared to provide customers with moderate prices. And these include second tier manufacturers, but I would say also some of the national brand manufacturers are also offering us opportunities to sell their products in a way that bite into any potential tariff increases. So The U.

S. Dental market growth is still impacted by staffing challenges and remains challenging to recruit hygienists. Office support also challenged, but not as bad as it was say a year ago. But practice productivity is going up. Dentists are investing in devices to increase productivity.

So I think it's for us in any way, in any event, it's leaning flat to slightly positive with opportunities and I think results in the specialty areas, in our medical business, in the software field. Clearly, customers are investing in software to increase productivity. So it's very difficult to give you specific data about countries outside of The United States. Canada is stable ish, I would say, but we're doing very, very well in Canada. I think some of that's because of our large customers, but generally for the normal customers as well, smaller retail, what we call the retail customers.

EMEA, we believe patient traffic is stable, particularly in governments where in markets where government reimbursement is there. So overall, I think we can report a relatively stable dental patient traffic market. I think that dentists are in good shape. They're buying. They're paying.

Cash flow is okay. Of course, there are all sorts of concerns, particularly in we noticed in the last six last half of the put it this way, in the middle of this quarter, there was a pullback on buying of equipment. I'm not saying dentists didn't place orders, but they didn't want shipments because of the potential tariff situation. But I think that's eased has gotten easier. It's eased a bit.

And the backlog is pretty good again. Interest rates are not an issue. We thought they would be about a year ago, but customers are accustomed to the interest rate now. As it relates to tariffs, I would say our customers fully understand that there are going to be tariff increases, that we can't absorb these tariff increases. And generally, where we passed on the tariff increases, they've stuck.

Yes, some customers will look to find alternative options, particularly on products and we are there with our own brands, products. One little wrinkle and that's the area of gloves that's become highly competitive. But I also believe that's going to be an area where Henry Schein will do okay because our brands are very good and we service all the various price offerings in gloves. So this has been a market that's been up and down for years and we continue to gain market share in the glove area. Sorry for the long answer, but that's a bit more of our take of what's happening.

Yes. Appreciate it, Stan. And just if I could just ask one quick follow-up. Know it's early days, but anything you can talk about with just the current state of the engagement and review with the outside consulting firms? I think there's revenue and cost opportunities for sure.

But can you give us a teaser at all as what's being emphasized or deemphasized? What are the savings opportunities that may have already been identified on top of the value creation projects that you already have underway?

Right. You point out correctly. There's two opportunities. One is the restructuring that we went through. And as Ron and I think I mentioned as well, we're over $100,000,000 in that area.

I think you'll see some more advantages in the third quarter. We'll provide you hopefully with more data at that time on our restructuring. Now the work we're doing with KKR, which started almost right after they told us they had invested in the business, involved dialogue with a capstone group, very capable people I might add, who have directed us in two areas. These areas align with our Bold plus one. The first is driving gross profit.

Now I don't want our customers to think we're just driving up prices because that's not what it's about. It's about providing value for our customers and of course gross margin enhancements for Henry Schein involving taking a look at our pricing and particularly seeing where there are options in areas such as own brands or with particular manufacturers that understand the value of Henry Schein and are prepared to work with us so that we can provide our customers with a better deal and also help us enhance our margins. That's a project that is going on. We started it in Europe already some months actually, I would say about five, six months ago, had pretty good results and are now working with an international, a very large consulting firm in doing this in The United States, all using the expertise of KKR's Capstone Group. And then we are the restructuring that we went through with respect to corporate overhead within our groups, that project we've done some good work in that area, but with the support of KKR's Capstone Group and the consulting firm that we've worked that we're working with, who've got great experience in working with complex companies, exactly the kind of organization we are in finding ways to develop global services versus perhaps services that we offer in each of our units.

There's a lot of opportunity here and we're hopeful and actually expect some good results in 2026. We're not ready to give mathematical numbers yet, but we will of course, with our restructuring plan taking us well over the $100,000,000 mark as well as these two key initiatives of gross margin enhancement and SG and A management. A lot of that is structural, a lot of AI possibilities that these firms have experience in bringing to us have experience and can bring to us. So we're quite optimistic in general about these two engagements. They've gone on now the dialogue has gone on with Capstone really as I said since they announced last summer or last fall, their engagement with us, their equity investment and these firms are now working with us and our team is extremely enthusiastic about this.

They know it's the right thing to do and we've got the teams working on it. In fact, I mentioned bumping into our sales management team on the Dental side that we have for that exact project for the gross margin management project last night. And all I can tell you is I think the value we create here will be very good for the company and therefore for our investors.

Our next question comes from Elizabeth Anderson with Evercore. Please proceed with your question.

Hi, guys. Good morning. And Stan, congratulations. It's been a pleasure. And wish you best in your retirement and your new role as Chairman.

Maybe switching to the question and maybe this is partly a question for Ron too. If we think about where we are in the year, we're halfway done and sort of thinking about the traditional EPS cadence in the back half of the year, I realize you said that there is $25,000,000 more of the Bold plus one initiatives plus obviously the 75,000,000 to 100,000,000 you talked about before. So how do we think about sort of the EPS cadence in the back half of the year, just vis a vis your guidance and sort of the year to date performance? Thank you.

Hi, Elizabeth. Thanks for the question. I think that, we did mention when we talked about our guidance that, even from the beginning of the year that we did expect to be more weighted to the back half of the year versus the first half of the year. So yes, we are expecting EPS to grow in the third quarter than I would say the fourth quarter to possibly exceed the third quarter as well. We're happy with the momentum we have coming into July, coming off the targeted sales initiatives we had.

We've been able to expand our sales team, on the distribution side. We think that's going to help us target some of these customers even better. We are confident in spite of some of the uncertainty, I'd say macroeconomic uncertainty we saw in the second quarter that we think impacted equipment sales. We're comfortable given where we are with the backlog that we'll begin to see some momentum with Dental equipment in the second half of the year. Our Specialty Products and Technology groups, we think we can maintain the momentum we have there.

The TaperPro conical continued to get good sequential growth during the year, and we think that can continue into Q3, Q4. So that should contribute to growth sequential growth for us. And you mentioned as well the restructuring plan. I think the restructuring plan has provided us with some cost savings. It will also as we get into some of these value creation projects, there will be perhaps opportunity to identify additional savings that working with the consultants, what could be some things that we haven't addressed fully.

And then lastly, did mention within the guidance that it does include, just as we have had in the last several years, remeasurement gains. And that could add a little bit to the lumpiness of this. Sometimes these remeasurement gains can be a little bit can be relative to the quarter, can be relatively large. So we will to the extent we end up with the remeasurement gain in the third quarter versus the fourth quarter that could impact that cadence. But obviously, it's something that we would alert investors to as part of our, when we report the earnings in terms of what is the impact of those remeasurement gains in the back half of the year.

Got it. That's super helpful. Thank you for that additional color. And if we think about sort of the ortho turnaround that you guys have been in process of implementing, can you tell us sort of the most recent updates on sort of where we are with the integration of the different Clearliner brands and how you would define the orthodontic environment more broadly? Obviously, I think you called out a little bit of weakness in the quarter, but just trying to triangulate whether that was macro or whether that's a result of your transition and that's something that could also happen with the help with the two second half gains.

Elizabeth, first of all, you for your nice comment at the beginning of your question. Second, on orthodontics, it is very small. It's under $100,000,000 business. There are two aspects. There's traditional, there's a particular product offering there that is of interest to customers, but it's very, very small.

It had generic competition a year ago plus for the past two, three years, starting about a year yes, about two, three years ago it started and we've now in the last six months to a year, we've stabilized that with an upgraded product. So the traditional part is doing well. We've cut is doing better is doing well, put it this way, on a reduced sales base. We reduced our sales organization, our cost, our marketing and it's really now moving into a positive environment in the traditional area. It's again not significant.

On the aligner side, we've moved the aligners to from a production point of view to the facility one facility in France. That's working quite well. Again, it's very, very small. We've reduced our sales and marketing expenses and it's not a significant area for Henry Schein other than with some DSOs who we've made arrangements with who try to buy most of their products from Henry Schein. I would not say that we are indicative of the growth of the market or the challenges of the market.

We have our internal areas we're working on and the goal there is to offer very good products on the traditional side, unique niche products, increase the margin and on the aligners have an offering that is unique that is integrated with some software we have. And I would say this is not for the moment a big strategic area for Henry Schein, but there are some profits there and we're turning around the business and making it more profitable. But again, it's very small $100,000,000 or so out of almost $13,000,000,000 of sales. So it's not material. But we'll give you updates as they materialize.

Our next question comes from Alan Lutz with Bank of America.

Stan, you mentioned July sales were good and you've returned to normal merchandise pricing. I guess a question for Ron here. How should we think about the gross margins in the distribution business in the second half of the year if you've returned to normal merchandise pricing? Can they go back to where they were a year ago? And then related to that around Capstone, should we view the gross margin initiatives as accretive to last year's gross margins as a starting point? Thank you.

Alan, in terms of gross margins, the distribution side, there is some very competitive areas. And we said that we did see some especially some pressure in glove pricing. I think on the glove pricing side, it has stabilized. I think sequentially, we can stabilize those margins.

I think versus last year, you're still going to see some slightly lower gross margins. That's just really the reality of where the market is, especially for when you have a product category as important as gloves that is seeing relatively competitive pricing out there. But we are seeing some stabilization in that glove pricing as we get into the third quarter. I think overall, as we look at margins, we're so happy with the growth we're seeing in technology, which given the margins in technology gives us an overall lift in gross margins as well as the growth we're seeing in the specialty products. Within specialty, we did see a little bit of a tick down in gross margin because we saw better growth in, for example, in value implants than we did in specialty.

Value implants typically get a slightly lower gross margins than I'm sorry, not specialty, but premium. And so but the value implants taking a little bigger piece of the pie brought down that segment's gross margin a little. But nevertheless, that's obviously accretive to our overall gross margin. So product mix will give us some benefit as we go forward. But certain product categories such as gloves will continue to put a little bit of pressure on gross margins and distribution. I think that, we're seeing some stabilization sequentially there.

Great. Thank you. And then one for Stan. Last quarter, you talked about an increase in de novo builds.

DSOs you mentioned were well financed and they're expanding. We'd love to get your updated thoughts on what you're seeing now. Is that still the case? Has that improved further? Any updated thoughts there would be helpful. Thank you.

Yes. I think we're pretty consistent with what the message of last quarter. The DSOs in general are moving in a positive direction. I think they're getting funding. If they trade, I'm not sure they're trading at this higher multiple as maybe a couple of years ago.

But generally the ones that are in the business have funding and are investing, some are even investing in traditional equipment. But dental technology is the digital side is where I would say there's quite a bit of movement and they're all investing one way or another in software. So I think it's pretty it's stable to maybe I'm thinking now maybe leaning even positive. There are a couple of places in the world where there's a challenge. France passed some laws that are a challenge but I would say even internationally they are growing and get funding and they're investing.

We didn't have any big sales this quarter, but generally every couple of quarters there's a big sale to a DSO and that's continuing. So here and abroad, would say it's positive and funding is available.

I just want to add on to what Stanley said there, Alan. I think that when we look in The U. We look at new office design projects, Every month this year, with the exception of one month, we have seen double digit growth year over year in kind of announced new office design projects. The one month that we didn't see that was in May, and we actually had double digit negative growth that month, which was an indication of a bit of the hesitation of uncertainty out there that was driven by tariffs or whatever it might have been. But every other month, we have seen double digit growth year over year.

Our next question comes from John Stansell with JPMorgan Chase. Please proceed with your question.

Great. Thanks for taking the question. Can you just size potentially the that targeted sales impact on the second quarter? And then just as we think back to this the first quarter call, what changed that led you to want to kind of pursue this targeted sales initiative and produce the kind of the positive impact that you're seeing now in July?

John, thank you. I'll address the second and Ron can potentially provide some thoughts on sales. I don't know what exactly we're providing to investors. It's not that we want to hide, but obviously for competitive reasons we need to be careful. We saw an opportunity with a group of customers in particular who in buying from Henry Schein returned to buy maybe exclusive products perhaps for cherry picking with us and used to buy in a more steady way, higher numbers.

And we felt there was just an opportunity, a hole in the bucket if you will, sales we lost over the last eighteen months. And to go to those customers with the equivalent of a frequent fire program, an affinity program that I think has been well received. And I don't think there's a need for this any longer. Maybe in such an aggressive way. But I think this high octane opportunity was just a hole that we felt we could go through and it has been relatively successful.

I think this is not a general offering to all of our customers, but it's an offering particularly to customers that we felt had left us, didn't understand us, didn't understand the value added services, gave our field sales representatives a reason to go into the office and gave our telesales representatives an opportunity to call and talk about in an outbound way about the values that Inrushchein brings. I think and all the value added services we offer. So I think it was a great opportunity and think the team went through that hole in the bucket and filled it. So thank you.

And John, regarding the first half of your question, we mentioned two things that kind of put pressure on those margins, right? One was lower glove pricing and the other was those targeted initiatives. As you can appreciate, there's a bit of an overlap there. Some of those targeted initiatives were on gloves because it's a very important product category. So it's difficult to really assess dollars and provide dollars to each of those individual items.

I think what's important out of all that is that we're pleased with the results we're seeing in July coming of those targeted initiatives and pleased also that we're seeing some stabilization in glove pricing. And so we consider it to be kind of a successful campaign and that gives us some confidence as we go into the back half of the year.

Great. And then there's been some discussion around one of your larger customers, RFP ing a portion of their business. Can you just comment generally on what you're seeing in the competitive balance as customers potentially RFP, especially on the DSO side? And maybe, Stanley, if you would indulge us in a bit of a retrospective about how these have changed what customers are looking for have changed over time as well would be helpful. Thank you.

Yes. Again, another good question there. We don't typically comment on contracts with specific customers. But I think it's normal for some of our larger customers to issue RFPs every three, four years or so. To some extent they want to see what our margin is, But to some extent, there's a negotiation with manufacturers because in the dental space, we actually perform the GPO function.

We work on behalf of our customers in obtaining pricing specifically related to them. And then we have put our markup on top of that. So I think this kind of activity is quite normal. It's not been actually as aggressive as we would have expected. And that is to some extent because we've worked well with our larger customers and finding alternative options to product sourcing where there is a significant tariff moving to other markets, to domestic products, moving to manufacturers that can absorb part of the tariff.

So I think generally we remain a very trusted supplier and are partnering with our customers quite well. So as it relates to trends, I think we continue to gain market share with our larger bigger midsize customers because of the comprehensive offering including our supply chain capabilities. I think it happens to be the best in the market. I'm sure our competitors will say theirs is the best. We do our work to ensure that from a service point of view we provide our customers with the best service, best in class.

But it's also our owned brand product offering, our private brand that is there and all the value added services that we provide. Generally, these larger customers are not only getting their consumables from us, but they're also getting the equipment and the service. I think our national service capability is outstanding, not only in The United States, but globally and it's best to practice. I'm sure our competitors will say theirs is best practice too. But I think we provide exceptional national coverage here and in many other countries.

So that is being recognized. And then there's the software opportunities and the various revenue cycle management opportunities where we can often save the customer more money or bring them more profits and perhaps a penny here or there on a glove box. So generally, I think the market is relatively stable from a large customer large midsize customer as well point of view. And everybody's working to understand the tariffs, working together and finding ways to mitigate these tariffs. I think it's a collaborative effort with our customers in general.

We have time for one last question, and that comes from the line of Jeff Johnson of Baird. Please proceed with your question.

You. Good morning, guys. Thanks Stanley, I think I met you in 2002 at our Growth Stock Conference in Chicago. We were both a lot younger then, but I've appreciated your steady hand and your consistent leadership over the years. So thank you and good luck in the future.

I was hoping I could start maybe, Ron, a question for you on gross margin. Just as you say, glove prices have stabilized, which sounds encouraging, but maybe going to be sequentially stable at these levels. How much of the 110 basis points of gross margin pressure this quarter in 2Q was maybe glove related, was promotional activity that sounds like it's gone away now and maybe was core pressures elsewhere? It would be helpful to just try to model out the half of this year by knowing gloves versus maybe those other two categories of gross margin pressure?

Yes. It's like I was saying, Jeff, it's hard to kind of isolate the programs when gloves are part of the programs. I think it's easier to look at it for us when we see the product categories, right? The product category for gloves probably attributed to about a third of margin pressure year over year, right, just gloves alone. And then the balance comes from just other competitive pricing and other competitive promotions that we've been doing.

Henry Schein (HSIC) Q2 2025 Earnings Call Transcript

Company Participants